Next Post

PolyPid licenses surgical infection prevention drug to Advanz

[ad_1] &#13 Israeli drug advancement company PolyPid (Nasdaq: PYPD) nowadays declared that it has entered into an special licensing settlement in Europe with Uk-centered specialty and medical center pharmaceutical business Advanz Pharma (previously Concordia Healthcare Corp.) for its guide drug candidate, D-PLEX100 for the avoidance of surgical internet site bacterial […]